Last reviewed · How we verify
rIL-21 only
At a glance
| Generic name | rIL-21 only |
|---|---|
| Sponsor | ZymoGenetics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer (PHASE2)
- Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients (PHASE2)
- Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rIL-21 only CI brief — competitive landscape report
- rIL-21 only updates RSS · CI watch RSS
- ZymoGenetics portfolio CI